Patents by Inventor Arnold Horwitz

Arnold Horwitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof
    Patent number: 11034759
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 15, 2021
    Assignees: Novartis Vaccines and Diagnostics, Inc., Xoma Technology Ltd.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20190263900
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: October 12, 2018
    Publication date: August 29, 2019
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF Specific Monoclonal Antibody and Uses Thereof
    Publication number: 20180171009
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 21, 2018
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses thereof
    Patent number: 9926371
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: March 27, 2018
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20170152311
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: June 1, 2017
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses therof
    Patent number: 9522186
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 20, 2016
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEROF
    Publication number: 20160015809
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: June 3, 2015
    Publication date: January 21, 2016
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins
    Patent number: 9096664
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: August 4, 2015
    Assignees: AVEO Pharmaceuticals, Inc., Xoma Technologies, Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses thereof
    Patent number: 9079956
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 14, 2015
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20140242071
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 28, 2014
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS VACCINES AND DIAGNOSTICS INC.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20140178935
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: October 2, 2013
    Publication date: June 26, 2014
    Applicant: AVEO PHARMACEUTICALS, INC.
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8580930
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: November 12, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20130203963
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: August 20, 2012
    Publication date: August 8, 2013
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Methods and materials for increasing expression of recombinant polypeptides
    Patent number: 8497096
    Abstract: The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of interest. The present invention provides expression vectors which contain multiple copies of a transcription unit encoding a polypeptide of interest separated by at least one selective marker gene and methods for sequentially transforming or transfecting host cells with expression vectors to increase transcription unit dosage and expression.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: July 30, 2013
    Assignee: XOMA Technology Ltd.
    Inventor: Arnold Horwitz
  • Method of treating inflammatory eye disease with IL-1? binding antibodies
    Patent number: 8377442
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: February 19, 2013
    Assignee: Xoma Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8273355
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: September 25, 2012
    Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20120014967
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Application
    Filed: May 17, 2011
    Publication date: January 19, 2012
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: Linda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell
  • Hepatocyte Growth Factor (HGF) Binding Proteins
    Publication number: 20110229462
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 22, 2011
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 7943344
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 17, 2011
    Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte Growth Factor (HGF) Binding Proteins
    Publication number: 20100173362
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: December 7, 2009
    Publication date: July 8, 2010
    Inventors: WILLIAM M. WINSTON, JR., S. KIRK WRIGHT, MAY HAN, LYNE BREAULT, JIE LIN, BIJAN ETEMAD-GILBERTSON, CHRISTINE KNUEHL, JENO GYURIS, ARNOLD HORWITZ